GSK grabs $1.25B cash and a cut of Gilead's megablockbuster Biktarvy sales as HIV rivals settle patent suit
Three years after ViiV Healthcare, the HIV specialist majority owned by GlaxoSmithKline, first sued Gilead over alleged patent infringement on one of its top drugs, the two companies have settled the case.
Gilead will pay ViiV $1.25 billion in cash — while agreeing to set aside a 3% royalty on all US sales of Biktarvy until October 2027.
A megablockbuster triplet therapy given as a daily pill, Biktarvy brought in $6.09 billion from the US alone in 2020. By 2027, Jefferies analysts estimate that cumulative US sales would reach about $50 billion — translating to about $2 billion in total royalties for ViiV.
To read Endpoints News become a free subscriber
Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters